iRhythm Technologies Azioni (NASDAQ: IRTC)

Ultime notizie per iRhythm Technologies (NASDAQ:IRTC) Azioni

iRhythm Technologies

iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies Inc

WIIM

Sherwin-Williams shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

NVDA

NVIDIA shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

News

Offerings

RDZN

Roadzen Files For Mixed Shelf Of Up To $100M

Contracts

ITRM

Iterum Therapeutics Notified Pfizer, Electing To Defer Milestone Payment For 2 Years For ORLYNVAH, Or Until Oct 25, 2026

The Symplicity &#x2122; blood pressure procedure offers patients a new adjunct approach to lowering blood pressure&nbsp;
GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral&#x2122;&nbsp;renal denervation (RDN) catheter, used in the Symplicity&#x2122;&nbsp;blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025, aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

Biotech

General

CMS grants Transitional Pass-Through Payment For Medtronic Symplicity Spyral Renal Denervation Catheter; Will Be Effective For Up To Three Years Beginning January 1, 2025

Titan International Files For Offering Of Up To 11.92M Shares By The Selling Stockholders

NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/NB#NASDAQ">NB</a>) today announced it has commenced a proposed underwritten public offering in the United States (the "Registered Offering"). Concurrently, the Company has also commenced a private placement (the "Private Offering" and, together with the Registered Offering, the "Offerings").
The Registered Offering consists of common shares and warrants to purchase common shares and is subject to market conditions. There can be no assurance as to whether or when the Registered Offering may be completed, or as to the actual size, pricing or other terms of the Registered Offering. In addition, the Company intends to grant the underwriter a 45-day over-allotment option to purchase up to an additional 15 percent of the number of initial common shares and/or an additional 15 percent of the number of initial warrants offered in the Registered Offering.
The Private Offering consists of common shares and warrants to purchase common shares. There can be no assurance as to whether or when the Private Offering may be completed, or as to the actual size, pricing or other terms of the Private Offering. Completion of the Private Offering is not contingent on completion of the Registered Offering and completion of the Registered Offering is not contingent on the completion of the Private Offering.
Maxim Group LLC is acting as sole book-running manager and underwriter for the Registered Offering.
NioCorp currently intends to use the net proceeds from the Offerings for working capital and general corporate purposes, including to (i) advance its efforts to launch construction of a critical minerals project in Southeast Nebraska (the "Elk Creek Project") and move it to commercial operation and (ii) repay all amounts outstanding under the Company's $2.0 million non-revolving multiple draw credit facility (the "Smith Credit Facility") available pursuant to the Loan Agreement, dated September 11, 2024, by and between the Company and its Chief Executive Officer, President and Executive Chairman, Mark Smith. The Smith Credit Facility will continue to be available to the Company following the close of the Offerings.
The Registered Offering is subject to customary closing conditions.

NioCorp Announces Commencement Of Proposed Underwritten Public Offering Of Common Shares & Warrants; No Size Or Amount Disclosed

CHWY

Chewy shares are trading higher after it was announced that the company will join the S&P MidCap 400 prior to the opening of trading on Wednesday, November 6, 2024.

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475162/1475162_djiadjuaintcdowaes.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475162/1475162_djiadjuaintcdowaes.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475162/1475162_djiadjuaintcdowaes.pdf</a>

Markets

NVIDIA And Sherwin-Williams Set To Join Dow Jones Industrial Average; Vistra To Join Dow Jones Utility Average

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475163/1475163_srcl4.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475163/1475163_srcl4.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475163/1475163_srcl4.pdf</a>

SRCL

Chewy Set to Join S&P MidCap 400; Chewy Will Replace Stericycle Inc In The S&P MidCap 400 Effective Prior To The Opening Of Trading On Wednesday, November 6

<a href="https://www.bloomberg.com/news/articles/2024-11-01/tesla-sells-499-million-of-debt-backed-by-solar-equipment-loans">https://www.bloomberg.com/news/articles/2024-11-01/tesla-sells-499-million-of-debt-backed-by-solar-equipment-loans</a>
Tesla Inc. sold $499 million of bonds backed by loans offered to customers buying solar equipment.

Financing

Asset Sales

TSLA

'Tesla Sells $499M Of Debt Backed by Solar Equipment Loans' - Bloomberg News

EVTV

Envirotech Vehicles Files Prospectus Relates To Resale, From Time To Time, Of Up To 13.6M Shares Of Common Stock

Global

BORR

Borr Drilling Limited Announces Voluntary Delisting From Oslo Stock Exchange; Co's Shares Will Be Delisted From OSE As Of 31 December 2024

ONCO

Onconetix Files For Resale Of Up To 10,586,556 Shares By The Selling Stockholders; Offering Up To 6.25M Shares Of Common Stock

- SEC Filing&nbsp;
On October 30, 2024, the Company received a letter from Nasdaq notifying the Company that, the Company had not regained compliance with the MVLS Requirement within the Cure Period. As a result, Nasdaq has determined to delist the Company's securities from Nasdaq on November 8, 2024, subject to the Company's right to appeal described below.
&nbsp;
On October 31, 2024, the Company requested a hearing to appeal such determination before a panel (the "Hearings Panel"). The hearing request will stay the suspension of the trading of the Company's common stock pending such hearing or any extension provided by the Hearings Panel.
&nbsp;
At such hearing, the Company intends to submit a plan to regain compliance with the MVLS Requirement and with other deficiencies in its compliance with Nasdaq listing requirements that have been previously disclosed, including the failure to comply with the minimum bid price requirement disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2024.
&nbsp;
No assurances can be provided that the Company will obtain a favorable decision from the Hearings Panel, and/or that the Company will be able to regain or maintain compliance with Nasdaq listing's rules.

CERO

CERo Therapeutics Received A Letter From Nasdaq Notifying The Company That It Had Not Regained Compliance With The MVLS Requirement Within The Cure Period; Nasdaq Has Determined To Delist The Company's Securities From Nasdaq On November 8, 2024; On October 31, 2024, The Co Requested A Hearing To Appeal The Determination Before A Panel

BNTC

Benitec Biopharma Files For Mixed Shelf Of Up To $125M

Super League Enterprise 13G Filing Shows Infinite Reality, Inc. Reported A 9.2% Stake In The Co As Of October 29, 2024

ITT Files For Mixed Shelf; Size Not Disclosed

ADAP

Adaptimmune Therapeutics Receives Nasdaq Notice For Non-Compliance With Minimum Bid Price

Marti Technologies, Inc. ("Marti" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRT#NYSE">MRT</a>), Türkiye's leading mobility super app, today announced that it has appointed Deniz Terlemez as its new Interim Chief Financial Officer ("CFO"), effective November 1, 2024. Deniz Terlemez succeeds Oguz Erkan, the Company's former CFO. Mr. Terlemez served as the Company's Finance Director before his appointment as Interim CFO.

Management

Marti Technologies Appoints  Deniz Terlemez As New Interim Chief Financial Officer, Effective November 1, 2024

Here are the major earnings after the close today

iRhythm Technologies Non-GAAP EPS of -$1.26 misses by $0.69, revenue of $147.5M beats by $0.78M

Reports Q3 revenue $$147.5M , consensus $146.73M."The third quarter of 2024 was an exceptional quarter of execution as our teams drove significant ...

iRhythm reports Q3 EPS($1.26) , consensus (57c)

iRhythm (IRTC) projects revenue for the full year 2024 to grow approximately 18% to 19% compared to prior year results, ranging from approximately ...

iRhythm sees FY24 revenue $$582.5M- $587.5M, consensus $585.33M

iRhythm (IRTC) Technologies announced that the U.S. FDA has granted clearance for its 510(k) submission related to design modifications and labelin...

iRhythm gets FDA 510(k) clearance for design modifications to Zio AT device

iRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript

Analyst Kallum Titchmarsh from Morgan Stanley maintained a Buy rating on Irhythm Technologies (IRTC – Research Report) and keeping the price target...

Irhythm Technologies: Buy Rating Affirmed on Promising Growth Prospects and Regulatory Progress

Truist Financial analyst Richard Newitter maintained a Buy rating on Irhythm Technologies (IRTC – Research Report) today and set a price target of ...

Irhythm Technologies (IRTC) Receives a Buy from Truist Financial

Irhythm Technologies (IRTC) has disclosed a new risk, in the Debt & Financing category. Irhythm Technologies faces a significant risk related to th...

iRhythm Technologies Faces Potential Stockholder Dilution and Market Pressure from 2029 Notes Conversion

Baird lowered the firm's price target on iRhythm (IRTC) to $79 from $100 and keeps an Outperform rating on the shares. The firm said its tough to a...

iRhythm price target lowered to $79 from $100 at Baird

ACGL

ACHC

AEIS

ALGT

ALTR

AMRN

AMSC

AMWL

ATEC

AXAHY

BECN

BKNG

HOOD

HTGC

HUBG

IMAX

INVH

IRTC

JAKK

KLAC

LMND

LPLA

MATX

MSFT

PPSI

RIOT

ROOT

SBUX

SIMO

SNBR

SPOK

SPXC

SSNLF

STAA

STEM

TDOC

TENB

Press Releases

iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence

Legal

Kaskela Law LLC Announces Shareholder Investigation of iRhythm Technologies, Inc. (NASDAQ: IRTC) and Encourages Long-Term IRTC Shareholders to Contact the Firm

IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC

IRHYTHM INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC

iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024

iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device

Health Care

Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy

Earnings

iRhythm Technologies Announces Third Quarter 2024 Financial Results

iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device

Artivion

Alphatec Holdings

AtriCure

Axonics

CeriBell

Conmed

Enovis

Glaukos

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRadimed

Integer Holdings Corporation Common Stock

Integer Holdings

LeMaitre Vascular

Masimo

Inari Medical

NovoCure

Envista Holdings Corporation Common Stock

Envista Holdings

Orthofix Medical

Omnicell

Penumbra

Pulse Biosciences

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

QuidelOrtho

TransMedics Gr

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

Baird

Needham

Truist Securities

Goldman Sachs

Canaccord Genuity

iRhythm Technologies shares are trading higher. Baird maintained an Outperform rating on the stock.

Comments

iRhythm Technologies

Notizie

Ultime notizie per iRhythm Technologies (NASDAQ:IRTC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO